- Cullinan Oncology Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed TranscriptFeb 14, 2023
- Cullinan Oncology Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call TranscriptMay 12, 2022
- Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 13, 2022
- Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar TranscriptMar 28, 2022
- Cullinan Oncology Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Cullinan Oncology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call TranscriptDec 16, 2021
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cullinan Oncology Inc Pearl Clinical Update Call TranscriptJun 04, 2021
Cullinan Oncology Inc at JPMorgan Healthcare Conference Transcript
Hi. Good morning. Welcome to the JPMorgan Healthcare Conference. I know it's final stretch on a Thursday, so really appreciate you all being here. My name is Raji Gunasekera with the healthcare investment banking team at JPM. Today, I'm pleased to introduce the team from Cullinan oncology, and we have their CEO, Nadim Ahmed. I'll hand it over to you.
Thank you very much. It's a pleasure to be here to share all of the exciting developments going on at Cullinan Oncology. Next slide is my disclaimer slide.
At Cullinan Oncology, we take a very unique approach to developing first-in-class and best-in-class programs through what we call our modality-agnostic targeted oncology approach. What that means is that the start of our discovery process, we identify a high-impact cancer targets, and it's only then that we think about the best vehicle to prosecute against those targets. So for us, it's always target, first; modality, second, rather than the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)